Science 37 Holdings, Inc (SNCE): Price and Financial Metrics

Science 37 Holdings, Inc (SNCE): $5.75

0.02 (+0.35%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

D

Add SNCE to Watchlist
Sign Up

Industry: Medical - Services

Industry

D

Ranked

#47 of 66

in industry

SNCE Price/Volume Stats

Current price $5.75 52-week high $12.96
Prev. close $5.73 52-week low $3.73
Day low $5.73 Volume 49,100
Day high $5.75 Avg. volume 43,227
50-day MA $5.60 Dividend yield N/A
200-day MA $5.84 Market Cap 34.33M

SNCE Stock Price Chart Interactive Chart >

SNCE Stock Summary

  • For SNCE, its debt to operating expenses ratio is greater than that reported by just 3.57% of US equities we're observing.
  • With a year-over-year growth in debt of -94.62%, SCIENCE 37 HOLDINGS INC's debt growth rate surpasses merely 0.99% of about US stocks.
  • In terms of volatility of its share price, SNCE is more volatile than 99.73% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to SCIENCE 37 HOLDINGS INC, a group of peers worth examining would be BSM, OLB, RNGR, METC, and POWW.
  • To check out SCIENCE 37 HOLDINGS INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001819113.

SNCE Valuation Summary

  • SNCE's price/sales ratio is 0.5; this is 77.27% lower than that of the median Healthcare stock.
  • SNCE's price/sales ratio has moved down 6.2 over the prior 38 months.

Below are key valuation metrics over time for SNCE.

Stock Date P/S P/B P/E EV/EBIT
SNCE 2023-12-29 0.5 0.6 -0.3 0.2
SNCE 2023-12-28 0.5 0.6 -0.3 0.2
SNCE 2023-12-27 0.5 0.6 -0.3 0.2
SNCE 2023-12-26 0.6 0.7 -0.3 0.2
SNCE 2023-12-22 0.4 0.5 -0.2 0.2
SNCE 2023-12-21 0.4 0.5 -0.2 0.3

Science 37 Holdings, Inc (SNCE) Company Bio


Science 37 Holdings, Inc. engages in enabling universal access for clinical research to accelerate the development of treatments for patients and providers. The company develops decentralized clinical trials (DCT) technology platform that enables modern and digital approaches to clinical research by bringing together all parties, including the patient and trial investigators, nurses, coordinators, as well as sponsors?to power workflows, centralize evidence generation, and harmonize data. It also offers Science 37 Metasite that provides networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating decentralized clinical trials. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, medical device, and biotech companies. The company was formerly known as Science 37, Inc. and changed its name to Science 37 Holdings, Inc. in October 2021. Science 37 Holdings, Inc. was founded in 2014 and is based in Culver City, California.


SNCE Latest News Stream


Event/Time News Detail
Loading, please wait...

SNCE Latest Social Stream


Loading social stream, please wait...

View Full SNCE Social Stream

Latest SNCE News From Around the Web

Below are the latest news stories about SCIENCE 37 HOLDINGS INC that investors may wish to consider to help them evaluate SNCE as an investment opportunity.

Science 37 Receives Top Honors in Everest PEAK Matrix®

Science 37 emerges as the only clinical trial site to be recognized as a Leader in Decentralized Clinical TrialsRESEARCH TRIANGLE PARK, N.C., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™ today announced that it has been named a Leader in the Decentralized Clinical Trials (DCT) PEAK Matrix® Assessment by the Everest Group, for the third consecutive year. The only clinical trial site to be named as a Leader in the PEAK

Yahoo | December 12, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning!

William White on InvestorPlace | December 11, 2023

Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc. Amended and Restated 2022 Employment Inducement Incentive Award Plan (the “Plan”). The Plan was approved by Science 37’s Board of Directors in November 2023. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Science 37’s Compensation Commit

Yahoo | December 7, 2023

Science 37 Holdings, Inc. Announces 1-for-20 Reverse Stock Split effective December 8, 2023

RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE) (“Science 37” or the “Company”), the clinical research industry-leading Metasite™, announced today that it will effect a 1-for-20 reverse stock split (“Reverse Stock Split”) of its outstanding common stock, par value $0.0001 per share (“Common Stock”), that will become effective on December 8, 2023, at 12:01 a.m., Eastern Time. Science 37’s Common Stock will continue to trade on The Nasdaq Ca

Yahoo | December 5, 2023

Science 37 Holdings, Inc. (NASDAQ:SNCE) Q3 2023 Earnings Call Transcript

Science 37 Holdings, Inc. (NASDAQ:SNCE) Q3 2023 Earnings Call Transcript November 12, 2023 Operator: Greetings and welcome to the Science 37 Third Quarter 2023 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Steve Halper from LifeSci Advisors. Thank you, Steve. You may […]

Yahoo | November 12, 2023

Read More 'SNCE' Stories Here

SNCE Price Returns

1-mo 0.17%
3-mo 7.68%
6-mo -28.13%
1-year 11.61%
3-year -97.15%
5-year N/A
YTD 7.68%
2023 -35.69%
2022 -96.67%
2021 16.87%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!